Recently, the Ciltacabtagene Autoleucel Injection (trade name: 卡卫荻/Carvykti), of Nanjing Legend Biotech Co., Ltd. is approved for marketing with conditions by China NMPA. It is indicated for the treatment of adults with relapsed or refractory multiple myeloma after three or more prior lines of therapy and progressed, including a proteasome inhibitor and an immunomodulatory agent.

The Ciltacabtagene Autoleucel Injection is an autologous cellular immunotherapy that involves integrating the chimeric antigen receptor (CAR) gene targeting B-cell maturation antigen (BCMA) into the patient's own peripheral blood T cells using a lentiviral vector, and recognizes the BCMA target on the surface of multiple myeloma cells and kills them, thus providing a treatment for multiple myeloma.

The marketing of this product provides a new treatment option for adult patients with multiple myeloma.